BG102708A - 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation - Google Patents
4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparationInfo
- Publication number
- BG102708A BG102708A BG102708A BG10270898A BG102708A BG 102708 A BG102708 A BG 102708A BG 102708 A BG102708 A BG 102708A BG 10270898 A BG10270898 A BG 10270898A BG 102708 A BG102708 A BG 102708A
- Authority
- BG
- Bulgaria
- Prior art keywords
- preparation
- application
- medicamentous
- preparations containing
- aminopyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996108631 DE19608631A1 (de) | 1996-03-06 | 1996-03-06 | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19629652A DE19629652A1 (de) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
PCT/EP1997/001057 WO1997032881A1 (de) | 1996-03-06 | 1997-03-03 | 4-amino-pyrimidin-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
BG102708A true BG102708A (en) | 1999-09-30 |
Family
ID=26023531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102708A BG102708A (en) | 1996-03-06 | 1998-08-20 | 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0885226A1 (xx) |
JP (1) | JP2000506847A (xx) |
KR (1) | KR19990087550A (xx) |
CN (1) | CN1212695A (xx) |
AU (1) | AU710274B2 (xx) |
BG (1) | BG102708A (xx) |
BR (1) | BR9708312A (xx) |
CA (1) | CA2243994A1 (xx) |
CZ (1) | CZ281798A3 (xx) |
DE (1) | DE19629652A1 (xx) |
EE (1) | EE9800277A (xx) |
HU (1) | HUP9901820A3 (xx) |
IL (1) | IL125404A0 (xx) |
NO (1) | NO984084D0 (xx) |
NZ (1) | NZ331546A (xx) |
PL (1) | PL328771A1 (xx) |
SK (1) | SK120598A3 (xx) |
TR (1) | TR199801749T2 (xx) |
WO (1) | WO1997032881A1 (xx) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
UA82517C2 (uk) * | 2003-06-24 | 2008-04-25 | Ньюросерч А/С | Нові похідні 8-аза-біцикло[3.2.1]октану та їх застосування як інгібіторів ресорбції моноамінових медіаторів |
CN101189238A (zh) * | 2005-02-16 | 2008-05-28 | 先灵公司 | 具有cxcr3拮抗剂活性的哌嗪-哌啶 |
WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
CN102216299B (zh) * | 2008-12-01 | 2015-02-11 | 默克专利有限公司 | 作为自体毒素抑制剂的2,5-二氨基取代的吡啶并[4,3-d]嘧啶化合物 |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
JP6297490B2 (ja) | 2011-08-31 | 2018-03-20 | ジェネンテック, インコーポレイテッド | 診断マーカー |
WO2013055530A1 (en) | 2011-09-30 | 2013-04-18 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
WO2014134202A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
EP2976085A1 (en) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
MX2017008421A (es) | 2014-12-24 | 2018-03-23 | Genentech Inc | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. |
RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
MA54547A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
ES2953821T3 (es) | 2018-12-20 | 2023-11-16 | Amgen Inc | Inhibidores de KIF18A |
MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
PE20230249A1 (es) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | Compuestos de heteroarilo biciclicos y usos de estos |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
WO2021097212A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
BR112022010086A2 (pt) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | Dosagem do inibidor de shp2 e métodos de tratamento de câncer |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DE4431867A1 (de) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/de not_active Ceased
-
1997
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/ko not_active Application Discontinuation
- 1997-03-03 JP JP9531444A patent/JP2000506847A/ja active Pending
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/hu unknown
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/xx unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/zh active Pending
- 1997-03-03 EP EP97907066A patent/EP0885226A1/de not_active Ceased
- 1997-03-03 NZ NZ331546A patent/NZ331546A/xx unknown
- 1997-03-03 IL IL12540497A patent/IL125404A0/xx unknown
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/de not_active Application Discontinuation
- 1997-03-03 BR BR9708312A patent/BR9708312A/pt not_active IP Right Cessation
- 1997-03-03 EE EE9800277A patent/EE9800277A/xx unknown
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/cs unknown
- 1997-03-03 SK SK1205-98A patent/SK120598A3/sk unknown
- 1997-03-03 PL PL97328771A patent/PL328771A1/xx unknown
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/xx unknown
- 1998-09-04 NO NO984084A patent/NO984084D0/no unknown
Also Published As
Publication number | Publication date |
---|---|
DE19629652A1 (de) | 1998-01-29 |
PL328771A1 (en) | 1999-02-15 |
IL125404A0 (en) | 1999-03-12 |
CN1212695A (zh) | 1999-03-31 |
NZ331546A (en) | 2000-03-27 |
EP0885226A1 (de) | 1998-12-23 |
AU710274B2 (en) | 1999-09-16 |
NO984084L (no) | 1998-09-04 |
SK120598A3 (en) | 1999-06-11 |
KR19990087550A (ko) | 1999-12-27 |
HUP9901820A3 (en) | 2001-10-29 |
NO984084D0 (no) | 1998-09-04 |
EE9800277A (et) | 1999-02-15 |
BR9708312A (pt) | 1999-08-03 |
CA2243994A1 (en) | 1997-09-12 |
TR199801749T2 (xx) | 1998-12-21 |
WO1997032881A1 (de) | 1997-09-12 |
JP2000506847A (ja) | 2000-06-06 |
HUP9901820A2 (hu) | 1999-09-28 |
CZ281798A3 (cs) | 1999-02-17 |
AU1925197A (en) | 1997-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG102708A (en) | 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation | |
ATE146360T1 (de) | Gonadotropin enthaltende gefriergetrocknete troepfen | |
NO931635D0 (no) | Fremgangsmaate for fremstilling av kinazolin-derivater | |
AP9901435A0 (en) | Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors. | |
RU94031102A (ru) | Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний | |
MX9700885A (es) | Nuevas heteroariloxazolidinonas. | |
BG103947A (en) | Derivatives of 9-oxymerythromycin | |
IE873125L (en) | Benzimidazole derivatives | |
MY131300A (en) | Antibacterial agents | |
BG103219A (en) | Benzamidine derivatives and their application as medicamentous forms with ltb-4-antagonist effect | |
MY115211A (en) | Novel amino acid derivatives, their preparation and use | |
ES2193246T3 (es) | Cefalosporinas antibacterianas. | |
TR199900661T2 (xx) | Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m� | |
AU8332791A (en) | Oral pharmaceutical compositions containing melatonin | |
GR3020355T3 (en) | Aminosulfonyl urea acat inhibitors | |
ES8703456A1 (es) | Procedimiento para preparar derivados de nitrofurano | |
AU3862997A (en) | Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof | |
BG102404A (en) | The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system | |
ES2018726A6 (es) | Procedimiento para preparar derivdos de mitomicina. | |
HK1008225A1 (en) | Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone | |
MX9701764A (es) | Derivados de imidoacidos. | |
MXPA02003731A (es) | Derivados novedosos de acido fusidico. | |
AU6722498A (en) | Disubstituted biphenyloxazolines | |
DE69627184D1 (de) | 3-aminoethyl-n-amidino-2,5-dihydropyrrol derivative mit arginine-mimetischen eigenschaften | |
GR3024709T3 (en) | Novel cytarabine derivatives, their production and use |